6-[(4-bromothiophen-2-yl)methoxy]-7H-purin-2-amine|192441-08-0,AngeneChemical

Contact Angene

Tel: +852 8191 6999

Email: [email protected]

Pyrimidine, 5-bromo-2-methyl-

1,3,5,2,4,6-Trioxatriphosphorinane, 2,4,6-tripropyl-, 2,4,6-trioxide

2,2'-Bi-1,3,2-dioxaborolane, 4,4,4',4',5,5,5',5'-octamethyl-

O=C(C=Cc1ccccc1)C=Cc1ccccc1.O=C(C=Cc1ccccc1)C=Cc1ccccc1.O=C(C=Cc1ccccc1)C=Cc1ccccc1.[Pd].[Pd]

Tris(dibenzylideneacetone)dipalladium

C1CCC(CC1)P(C1CCCCC1)C1CCCCC1.Cc1cc(C)c(c(c1)C)N1CCN(C1=[Ru](=Cc1ccccc1)(Cl)Cl)c1c(C)cc(cc1C)C

Ruthenium,[1,3-bis(2,4,6-trimethylphenyl)-2-imidazolidinylidene]dichloro(phenylmethylene)(tricyclohexylphosphine)-, (SP-5-41)-

6-[(4-bromothiophen-2-yl)methoxy]-7H-purin-2-amine

Request for Quotation

Chemical Name:	6-[(4-bromothiophen-2-yl)methoxy]-7H-purin-2-amine
CAS Number:	192441-08-0
Product Number:	AG002FYO(AGN-PC-0KO1R0)
Synonyms:
MDL No:	MFCD09837804
Molecular Formula:	C10H8BrN5OS
Molecular Weight:	326.1724

Identification/Properties
Safety Information
NMR Spectrum
Other Analytical Data
Customer Feedback

Identification/Properties

Computed Properties

Molecular Weight:

326.172g/mol

XLogP3:

Hydrogen Bond Donor Count:

Hydrogen Bond Acceptor Count:

Rotatable Bond Count:

Exact Mass:

324.963g/mol

Monoisotopic Mass:

324.963g/mol

Topological Polar Surface Area:

118A^2

Heavy Atom Count:

Formal Charge:

Complexity:

299

Isotope Atom Count:

Defined Atom Stereocenter Count:

Undefined Atom Stereocenter Count:

Defined Bond Stereocenter Count:

Undefined Bond Stereocenter Count:

Covalently-Bonded Unit Count:

Compound Is Canonicalized:

Yes

Safety Information

GHS Pictogram:

Signal Word:

Warning

UN#:

Hazard Statements:

H302

Precautionary Statements:

P280-P305+P351+P338

Class:

Packing Group:

NMR Spectrum

Other Analytical Data

Request for Quotation

Quantity Required:*

Company Name:

Contact Person:*

Email:*

Tel:*

Country:*

Others:(Optional)

Verification Code:

Customer Feedback

Chemical Structure

Lomeguatrib is a potent chemotherapeutic agent that plays a crucial role in chemical synthesis, particularly in the development of pharmaceuticals and other bioactive compounds. As a competitive inhibitor of the DNA repair enzyme O6-alkylguanine-DNA alkyltransferase (AGT), Lomeguatrib effectively sensitizes cancer cells to alkylating agents by preventing the repair of O6-alkylguanine lesions in DNA. This mechanism of action makes Lomeguatrib a valuable tool in designing new drugs for cancer therapy.In chemical synthesis, Lomeguatrib is utilized as a key building block in the creation of novel AGT inhibitors or as a structural motif in designing customized small molecules with specific pharmacological activities. Its versatile reactivity and ability to form stable complexes with AGT have opened up opportunities for creating targeted therapies that selectively disrupt DNA repair mechanisms in cancer cells, leading to enhanced treatment outcomes and reduced side effects.Overall, the application of Lomeguatrib in chemical synthesis demonstrates its potential to drive innovation in drug discovery and design, offering new strategies for combating cancer and other diseases at the molecular level.